Diabetalong
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Analogs
- 9. Terms and conditions of storage
- 10. Terms of dispensing from pharmacies
Prices in online pharmacies:
from 139 rub.
Buy
Diabetalong is a second generation sulfonylurea derivative, a hypoglycemic drug for oral administration.
Release form and composition
Dosage form - prolonged-release tablets (60 mg) and modified-release tablets (30 mg): flat-cylindrical, almost white or white, with a bevel, surface marbling is allowed; 60 mg tablets - flat, with a dividing line (in a blister strip: 60 mg - 10 pcs., in a cardboard box 1, 2, 3 or 6 packs; 20 pcs., in a cardboard box 1, 3, 5 or 6 packs; 30 mg each - 10 pcs., in a cardboard box 3 or 6 packs).
1 tablet contains:
- active substance: gliclazide - 60 mg or 30 mg;
- auxiliary components: aerosil (colloidal silicon dioxide), calcium stearate, tablettose 80 (lactose monohydrate), hypromellose (Metocel K-100 LV CR Premium), talc.
In addition, in tablets with prolonged release in the composition of hypromellose - Metolose 90 SH-100SH.
Indications for use
The use of Diabetalong is indicated for the treatment of type 2 diabetes mellitus in the absence of a sufficient effect from diet therapy, exercise and weight loss.
In addition, extended-release tablets are prescribed for the prevention of complications of diabetes mellitus in order to reduce the risk of developing retinopathy, nephropathy, myocardial infarction, stroke through intensive glycemic control in type 2 diabetes mellitus.
Contraindications
- type 1 diabetes mellitus;
- diabetic ketoacidosis, diabetic precoma, diabetic coma;
- concomitant therapy with miconazole;
- severe hepatic and / or renal impairment;
- period of pregnancy;
- breast-feeding;
- age up to 18 years;
- lactase deficiency, glucose-galactose malabsorption syndrome, lactose intolerance;
- concomitant use of phenylbutazone or danazol;
- hypersensitivity to sulfonamides, other sulfonylurea derivatives, drug components.
With caution, it is necessary to prescribe Diabetalong to patients with irregular nutrition and / or not observing its balance, deficiency of glucose-6-phosphate dehydrogenase, severe diseases of the cardiovascular system (including ischemic heart disease, atherosclerosis), hypopituitarism, hypothyroidism, adrenal or hypothyroidism, or hypothyroidism / or liver failure, long-term use of glucocorticosteroids, suffering from alcoholism, in old age.
Method of administration and dosage
The tablets are taken orally, swallowing whole, preferably during breakfast, once a day.
The dose of the drug should be determined by the selection method, taking into account the individual concentration of glucose and glycosylated hemoglobin in the blood.
1 tablet of 60 mg is equivalent to the therapeutic effect of 2 tablets of 30 mg. The dividing risk on 60 mg tablets allows, if necessary, to divide it into two parts. If, as a result of division, half of the tablet crumbles, it should not be taken.
Recommended daily dosage: initial dose (including patients over 65 years of age) - 30 mg, with an adequate response, it is used as a maintenance dose. In the absence of sufficient glycemic control, the daily dose must be sequentially increased (no more than 1 time in 4 weeks) to 60, 90 or 120 mg. If a decrease in the concentration of glucose in the blood does not occur after 2 weeks of taking the pills, then the dose is increased with a 2-week interval.
Do not take a higher dose after missing one or more doses.
The maximum daily dose is 120 mg.
When switching from another oral hypoglycemic agent, its dose and half-life must be taken into account.
If the previous drug of sulfonylurea derivatives had a long half-life, it is recommended to take a break from taking several doses before starting the drug. This will avoid hypoglycemia against the background of the additive effect of two hypoglycemic agents. Close monitoring of blood glucose levels is required for several weeks.
The initial dose of Diabetalong should always be 30 mg.
Tablets are indicated in combination with hypoglycemic agents such as biguanides, alpha-glucosidase inhibitors or insulin.
Patients with mild to moderate renal insufficiency are indicated for the usual dose of the drug, but treatment should be carried out under close medical supervision.
Since patients with insufficient or unbalanced nutrition, severe or poorly compensated endocrine disorders (hypothyroidism, pituitary and adrenal insufficiency), severe pathologies of the cardiovascular system (ischemic heart disease, generalized atherosclerosis, atherosclerosis of the carotid arteries) or after the cancellation of long-term therapy and / or therapy in high doses, glucocorticosteroids are at risk of developing hypoglycemia, they should be prescribed no more than 30 mg of the drug per day.
To prevent complications of diabetes mellitus during the period of use of the drug, patients should follow the diet recommended by the doctor, exercise regularly, and in case of deterioration, immediately consult a doctor.
Side effects
- the development of hypoglycemia: symptoms - a strong feeling of hunger, increased sweating, weakness, clammy skin, headache, nausea, vomiting, increased fatigue, irritability, sleep disturbance, agitation, slow response, decreased concentration, depression, impaired vision and speech, confusion, aphasia, tremor, feeling of helplessness, paresis, loss of self-control, impaired perception, dizziness, drowsiness, bradycardia, delirium, shallow breathing, convulsions, anxiety, tachycardia, increased blood pressure, arrhythmia, angina pectoris, palpitations, loss of consciousness, coma, lethal Exodus;
- from the gastrointestinal tract: nausea, vomiting, abdominal pain, diarrhea, constipation;
- dermatological reactions: itching, skin rash, urticaria, erythema, Quincke's edema, maculopapular rash, toxic epidermal necrolysis, Stevens-Johnson syndrome;
- on the part of the hematopoietic and lymphatic system: transient hematological disorders - leukopenia, anemia, thrombocytopenia, granulocytopenia;
- from the hepatobiliary system: increased activity of alkaline phosphatase, aspartate aminotransferase (ACT), alanine aminotransferase (ALT); in isolated cases - hepatitis, cholestatic jaundice;
- on the part of the senses: transient visual disturbances (more often at the beginning of therapy);
- others: possibly (side effects common to sulfonylurea derivatives) - severe hepatic failure, agranulocytosis, erythrocytopenia, hemolytic anemia, allergic vasculitis, pancytopenia, hyponatremia.
special instructions
Against the background of the use of Diabetalong, like other sulfonylurea derivatives, there is a risk of hypoglycemia. To relieve her symptoms, the patient should urgently take any product containing carbohydrates (sugar is possible), sugar substitutes are not effective in this case.
In the case of a severe and prolonged form of hypoglycemia, the patient needs hospitalization and intravenous administration of dextrose solution for several days.
When prescribing the drug, the patient and his family members should be thoroughly informed about the need to strictly adhere to a regular meal, including breakfast, the risk and symptoms of hypoglycemia, as well as conditions conducive to its development. Since irregular, inadequate or low carbohydrate diets increase the risk of hypoglycemia, it is very important to follow all your doctor's recommendations.
In addition to a low-calorie diet, the cause of hypoglycemia is often prolonged or vigorous physical activity, alcohol consumption, or the simultaneous use of several hypoglycemic agents.
Consideration should be given to the possibility of a relapse of hypoglycemia after successful initial relief.
The following factors influence the risk of developing hypoglycemia:
- unwillingness or inability of the patient (usually the elderly) to control his condition and strictly follow the doctor's orders;
- non-compliance with the regime and diet;
- imbalance between carbohydrate intake and physical activity;
- simultaneous use of drugs that enhance the hypoglycemic effect of the drug;
- severe liver failure;
- renal failure;
- pathology of the thyroid gland, adrenal and pituitary insufficiency;
- overdose of Diabetalong.
Changes in the pharmacokinetic and / or pharmacodynamic properties of gliclazide in patients with renal and hepatic insufficiency have a negative effect on the severity of hypoglycemia in the event of its development.
It is advisable to accompany the drug intake with regular self-monitoring of blood glucose concentration.
With a deficiency of glucose-6-phosphate dehydrogenase, the drug can contribute to the development of hemolytic anemia, therefore it is recommended to consider the possibility of prescribing a hypoglycemic agent of another group.
In the case of an infectious disease or major surgery, consideration should be given to the possible discontinuation of drug therapy and the appointment of insulin therapy.
The reason for the trend towards a decrease in the hypoglycemic effect of Diabetalong after prolonged use can be both a decrease in the therapeutic response and the progression of the disease. When diagnosing secondary drug resistance, the physician must carefully assess the adequacy of the patient's dose and ensure that they are following the prescribed diet.
Taking the drug with breakfast reduces the risk of side effects from the gastrointestinal tract.
In severe hepatic and / or renal failure, the patient is advised to use insulin.
When planning a pregnancy or in case of conception while taking the drug, a woman is recommended to switch to insulin therapy.
Given the risk of hypoglycemia, during the period of drug use, patients are advised to be careful when driving vehicles and mechanisms.
Drug interactions
With the simultaneous use of Diabetalong:
- miconazole significantly enhances the effect of gliclazide;
- when administered systemically, phenylbutazone helps to displace gliclazide from its connection with blood plasma proteins and / or slow down its excretion from the body, increasing the hypoglycemic effect of the drug;
- ethanol (including alcohol and ethanol-containing drugs) increases the risk of hypoglycemia, may cause hypoglycemic coma;
- Other hypoglycemic agents (insulin, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, agonists of glucagon-like peptide-1), beta-blockers, fluconazole, angiotensin converting enzyme inhibitors (captopril, enalapril), blockers of H 2 histamine receptors, monoamine oxidase inhibitors, sulfonamides, clarithromycin, nonsteroidal anti-inflammatory drugs - increase the hypoglycemic effect of the drug and the risk of hypoglycemia;
- Danazol has a diabetogenic effect, reducing the clinical effect of the drug;
- chlorpromazine at a dose above 100 mg per day, reducing insulin secretion, increases the concentration of glucose in the blood;
- tetracosactide and glucocorticosteroids for systemic and local use increase the concentration of glucose in the blood, can reduce tolerance to carbohydrates and cause the development of ketoacidosis;
- salbutamol, ritodrin, terbutaline for intravenous administration increase the level of glucose in the blood;
- warfarin and other anticoagulants can increase their effect.
Analogs
Analogs of Diabetalong are: Diabinax, Gliclazid MV, Gliclazid-Akos, Glidiab MV, Diabeton MV, Glucostabil.
Terms and conditions of storage
Keep out of the reach of children.
Store at temperatures up to 25 ° C in a dark place.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Diabetalong: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Diabetalong 30 mg sustained-release tablets 60 pcs. 139 RUB Buy |
|
Diabetalong 60 mg sustained release tablets 30 pcs. 141 r Buy |
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
